Associations between COVID-19 and hospitalisation with respiratory and non-respiratory conditions: a record linkage study.
COVID-19
Epidemiology
Hospitals
Public health
SARS-COV-2
Journal
The Medical journal of Australia
ISSN: 1326-5377
Titre abrégé: Med J Aust
Pays: Australia
ID NLM: 0400714
Informations de publication
Date de publication:
16 01 2023
16 01 2023
Historique:
revised:
20
09
2022
received:
15
02
2022
accepted:
23
09
2022
pubmed:
16
11
2022
medline:
18
1
2023
entrez:
15
11
2022
Statut:
ppublish
Résumé
To assess associations between SARS-CoV-2 infection and the incidence of hospitalisation with selected respiratory and non-respiratory conditions in a largely SARS-CoV-2 vaccine-naïve population . Self-control case series; analysis of population-wide surveillance and administrative data for all laboratory-confirmed COVID-19 cases notified to the Victorian Department of Health (onset, 23 January 2020 - 31 May 2021; ie, prior to widespread vaccination rollout) and linked hospital admissions data (admission dates to 30 September 2021). Hospitalisation of people with acute COVID-19; incidence rate ratios (IRRs) comparing incidence of hospitalisations with defined conditions (including cardiac, cerebrovascular, venous thrombo-embolic, coagulative, and renal disorders) from three days before to within 89 days of onset of COVID-19 with incidence during baseline period (60-365 days prior to COVID-19 onset). A total of 20 594 COVID-19 cases were notified; 2992 people (14.5%) were hospitalised with COVID-19. The incidence of hospitalisation within 89 days of onset of COVID-19 was higher than during the baseline period for several conditions, including myocarditis and pericarditis (IRR, 14.8; 95% CI, 3.2-68.3), thrombocytopenia (IRR, 7.4; 95% CI, 4.4-12.5), pulmonary embolism (IRR, 6.4; 95% CI, 3.6-11.4), acute myocardial infarction (IRR, 3.9; 95% CI, 2.6-5.8), and cerebral infarction (IRR, 2.3; 95% CI, 1.4-3.9). SARS-CoV-2 infection is associated with higher incidence of hospitalisation with several respiratory and non-respiratory conditions. Our findings reinforce the value of COVID-19 mitigation measures such as vaccination, and awareness of these associations should assist the clinical management of people with histories of SARS-CoV-2 infection.
Identifiants
pubmed: 36377203
doi: 10.5694/mja2.51778
pmc: PMC10100490
doi:
Substances chimiques
COVID-19 Vaccines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
33-39Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2022 The Authors. Medical Journal of Australia published by John Wiley & Sons Australia, Ltd on behalf of AMPCo Pty Ltd.
Références
Lancet. 2021 Aug 14;398(10300):599-607
pubmed: 34332652
Nat Med. 2022 Feb;28(2):410-422
pubmed: 34907393
BMJ. 2016 Sep 12;354:i4515
pubmed: 27618829
JAMA. 2022 Sep 6;328(9):887-889
pubmed: 35867050
Lancet Infect Dis. 2022 Apr;22(4):e102-e107
pubmed: 34951953
BMJ. 2021 Aug 26;374:n1931
pubmed: 34446426
Stroke. 2021 May;52(5):1895-1904
pubmed: 33794655
Eur Stroke J. 2020 Mar;5(1):26-35
pubmed: 32232167
Eur Heart J. 2021 Aug 31;42(33):3127-3142
pubmed: 34164664
Nat Med. 2022 Mar;28(3):583-590
pubmed: 35132265
CMAJ. 2021 Jan 4;193(1):E10-E18
pubmed: 33293424
Am Heart J. 2021 Jan;231:93-95
pubmed: 33181067
Lancet Reg Health West Pac. 2021 Dec;17:100297
pubmed: 34723232
Commun Dis Intell (2018). 2020 Nov 24;44:
pubmed: 33357173
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Med J Aust. 2022 Mar 7;216(4):199-201
pubmed: 34808695
Thromb Res. 2019 Sep;181:71-76
pubmed: 31357146
Lancet Neurol. 2020 Sep;19(9):767-783
pubmed: 32622375
Lancet Infect Dis. 2022 Aug;22(8):1142-1152
pubmed: 35576963
JAMA Neurol. 2020 Jul 02;:
pubmed: 32614385
Circulation. 2020 Nov 24;142(21):2080-2082
pubmed: 33054349